← Back to headlines
Bristol-Myers Signals R&D Cycle-Time Reduction and Strong 2026 Guidance
Bristol-Myers has indicated a target of 30% reduction in R&D cycle-time and is tracking towards the upper end of its 2026 financial guidance ranges.
30 Apr, 19:53 — 30 Apr, 19:53
Sources
Showing 1 of 1 sources
